The Pentagon’s recent initiative to screen service members for testosterone deficiency has sparked a debate about the potential consequences for veterans’ healthcare. Secretary Pete Hegseth’s proposal to annually test service members aged 30 and older, and offer therapy to those with low levels, has drawn criticism from medical experts and lawmakers alike.
The primary concern revolves around the long-term management of hormone therapy for veterans. Dr. Adrian Dobs, a professor of medicine and oncology at Johns Hopkins University School of Medicine, warns that testosterone therapy can suppress natural hormone production and sperm counts, creating a dependency on the treatment. This dependency could pose significant challenges for the Department of Veterans Affairs (VA), which has already struggled with managing hormone therapy for veterans.
Medical experts warn of overprescription and fertility risks
Medical professionals have expressed apprehension about the potential for overprescription of testosterone therapy. Dr. Alvin Matsumoto, a professor emeritus at the University of Washington School of Medicine, emphasizes that a single low testosterone test is not sufficient to diagnose a deficiency. He notes that about a third of men with initially low testosterone levels test normal upon retesting.
The Endocrine Society’s clinical practice guidelines, which Matsumoto helped develop, recommend that doctors establish symptoms and repeatedly low testosterone levels before beginning treatment. This cautious approach is crucial to avoid treating men who do not actually have hypogonadism a condition characterized by abnormally low testosterone levels.
Moreover, the potential impact on fertility is a significant concern. Dr. Dobs highlights that men who take testosterone will experience a reduction in their sperm counts, which could have long-term repercussions for those planning to start a family.
VA’s past struggles with hormone therapy management
A 2018 review by the VA Office of Inspector General revealed that providers often started patients on testosterone without adequately documenting symptoms or confirming low testosterone levels. Approximately two-thirds of patients did not receive a documented discussion of the risks and benefits of the treatment before starting. This history of inadequate management raises questions about the VA’s ability to handle the increased demand for hormone therapy that may result from the Pentagon’s initiative.
The inspector general’s review also found that providers frequently failed to conduct recommended follow-up after treatment began. This lack of oversight could lead to unnecessary treatment and potential health risks for veterans. The VA has since implemented seven recommendations to bring its practices up to standard, including repeat testing and monitoring. However, the effectiveness of these changes remains to be seen.
The financial and logistical challenges ahead
The financial implications of the Pentagon’s initiative are also a cause for concern. Dr. Dobs questions who will bear the cost of testosterone therapy for service members during their active duty and after they transition to the VA. The long-term financial burden could be substantial, especially considering the potential need for continued clinical monitoring to ensure patients are not receiving excessive amounts of the hormone.
Additionally, the logistical challenges of transitioning service members from Pentagon care to VA care are significant. Matsumoto emphasizes the importance of reviewing why treatment was started in the first place, including whether the patient had symptoms and repeatedly low testosterone levels. However, he does not expect this reassessment to routinely happen, which could lead to continued treatment without proper justification.
The Pentagon’s initiative also raises questions about the lack of consideration for women’s health. Rep. Chrissy Houlahan, D-Pa., an Air Force veteran, points out that testosterone is important for both men and women. She criticizes the initiative for focusing solely on men’s health and not addressing the unique challenges faced by women in the military.
As the Pentagon moves forward with its testosterone screening initiative, the potential impacts on veterans’ healthcare and the challenges of managing hormone therapy remain significant concerns. The need for careful oversight, adequate funding, and comprehensive consideration of all service members’ health needs is Paramount.
